What if a trade deal made life-saving medicines even more expensive—even after patents expire?
Our latest blog breaks down the proposed Kenya–UAE Free Trade Agreement and how it risks blocking affordable generics by introducing TRIPS-plus provisions like market exclusivity and patent linkage. In a time of shrinking aid and rising costs, we cannot afford to hand our health system over to pharmaceutical monopolies.
Read the article and join the call: No trade deal should come at the cost of Kenyan lives.
